Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1994 2
1996 4
1997 4
1998 1
1999 2
2000 2
2003 1
2005 1
2006 3
2008 1
2009 3
2010 6
2011 6
2012 6
2013 2
2014 5
2015 8
2016 5
2017 5
2018 8
2019 9
2020 12
2021 6
2022 4
2023 8
2024 7
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

111 results

Results by year

Filters applied: . Clear all
Page 1
Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39).
Moore KN, Bookman M, Sehouli J, Miller A, Anderson C, Scambia G, Myers T, Taskiran C, Robison K, Mäenpää J, Willmott L, Colombo N, Thomes-Pepin J, Liontos M, Gold MA, Garcia Y, Sharma SK, Darus CJ, Aghajanian C, Okamoto A, Wu X, Safin R, Wu F, Molinero L, Maiya V, Khor VK, Lin YG, Pignata S. Moore KN, et al. Among authors: robison k. J Clin Oncol. 2021 Jun 10;39(17):1842-1855. doi: 10.1200/JCO.21.00306. Epub 2021 Apr 23. J Clin Oncol. 2021. PMID: 33891472 Free PMC article. Clinical Trial.
Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer.
Vergote I, Pérez-Fidalgo JA, Hamilton EP, Valabrega G, Van Gorp T, Sehouli J, Cibula D, Levy T, Welch S, Richardson DL, Guerra EM, Scambia G, Henry S, Wimberger P, Miller DS, Klat J, Martínez-Garcia J, Raspagliesi F, Pothuri B, Romero I, Bergamini A, Slomovitz B, Schochter F, Høgdall E, Fariñas-Madrid L, Monk BJ, Michel D, Kauffman MG, Shacham S, Mirza MR, Makker V; ENGOT-EN5/GOG-3055/SIENDO Investigators. Vergote I, et al. J Clin Oncol. 2023 Dec 10;41(35):5400-5410. doi: 10.1200/JCO.22.02906. Epub 2023 Sep 5. J Clin Oncol. 2023. PMID: 37669480 Clinical Trial.
Editorial: Second-generation sequencing.
Robison K. Robison K. Brief Bioinform. 2010 Sep;11(5):455-6. doi: 10.1093/bib/bbq066. Brief Bioinform. 2010. PMID: 20861023 No abstract available.
Pelvic floor disorders in women with gynecologic malignancy.
Hall E, Robison K, Wohlrab K. Hall E, et al. Among authors: robison k. Curr Opin Obstet Gynecol. 2018 Dec;30(6):446-450. doi: 10.1097/GCO.0000000000000500. Curr Opin Obstet Gynecol. 2018. PMID: 30299322 Review.
Deadly Legacy-The 510(k) Path to Medical Device Clearance.
Adashi EY, Robison KM, Cohen IG. Adashi EY, et al. Among authors: robison km. JAMA Surg. 2022 Mar 1;157(3):185-186. doi: 10.1001/jamasurg.2021.5558. JAMA Surg. 2022. PMID: 34910095 No abstract available.
Ovarian Cancer Risk-Reduction and Screening in BRCA1/2 Mutation Carriers.
DiSilvestro JB, Haddad J, Robison K, Beffa L, Laprise J, Scalia-Wilbur J, Raker C, Clark MA, Lokich E, Hofstatter E, Dalela D, Brown A, Bradford L, Toland M, Stuckey A. DiSilvestro JB, et al. Among authors: robison k. J Womens Health (Larchmt). 2024 May;33(5):624-628. doi: 10.1089/jwh.2023.0621. Epub 2024 Mar 15. J Womens Health (Larchmt). 2024. PMID: 38488054
Financial toxicity in BRCA1 and BRCA2 carriers.
Proussaloglou EM, Rosenthal AE, Raker CA, Wilbur JS, Stuckey AR, Robison KM. Proussaloglou EM, et al. Among authors: robison km. Gynecol Oncol. 2023 Mar;170:160-166. doi: 10.1016/j.ygyno.2023.01.007. Epub 2023 Jan 24. Gynecol Oncol. 2023. PMID: 36701836
111 results